Business Wire

30 May 2026, 16:00 UTC · 2h ago

Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

Source · https://www.businesswire.com/news/home/20260530475386/en/Mirum-Pharmaceuticals-Announces-New-Data-from-Rare-Liver-Disease-Programs-Presented-at-the-EASL-International-Liver-Congress-2026/

Read source

Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

Search tags

Story key points

0 claims · impact-rated

What matters in this story

No key-points head found for this article.

Ticker attribution

Model heads

Sentiment in this article

MIRM+0.50
Company announced new data from its rare liver disease programs, which typically signals positive clinical progress.

Relationships in this article

No ticker relationship head found.

Impact vectors

2 dimensions · 9 clusters

Analytical profile by cluster

Market Behaviour+0.300

6 related stories

Reuters
3h ago
Mineralys' pill cuts blood pressure in kidney disease patients
- biotech
- pharmaceuticals
Read

News Impact Screener — Catch market-moving news before the crowd

Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

What matters in this story

Sentiment in this article

Relationships in this article

Analytical profile by cluster

Mineralys' pill cuts blood pressure in kidney disease patients

Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

What matters in this story

Sentiment in this article

Relationships in this article

Analytical profile by cluster

Mineralys' pill cuts blood pressure in kidney disease patients

Top impact dimensions

Most positively impacted

Most negatively impacted

Moderna, Inc. (MRNA) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript

INVESTOR NOTICE: Medpace Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - MEDP

MannKind Corporation (MNKD) Discusses FDA Approval of Afrezza for Pediatric Diabetes Patients Ages 6 and Older Transcript

IMMP Investors Have Opportunity to Lead Immutep Ltd. Securities Fraud Lawsuit

Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs

Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

What matters in this story

Sentiment in this article

Relationships in this article

Analytical profile by cluster

Next reads from the same story arc

Mineralys' pill cuts blood pressure in kidney disease patients

Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

What matters in this story

Sentiment in this article

Relationships in this article

Analytical profile by cluster

Next reads from the same story arc

Mineralys' pill cuts blood pressure in kidney disease patients

Top impact dimensions

Most positively impacted

Most negatively impacted

Moderna, Inc. (MRNA) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript

INVESTOR NOTICE: Medpace Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - MEDP

MannKind Corporation (MNKD) Discusses FDA Approval of Afrezza for Pediatric Diabetes Patients Ages 6 and Older Transcript

IMMP Investors Have Opportunity to Lead Immutep Ltd. Securities Fraud Lawsuit

Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs